Wegovy cuts heart risk by 57% vs. Lilly in weight-loss study

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly’s rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.

See the original article at: Honolulu Star-Advertiser